Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
  • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
  • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L39/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions of derivatives of such polymers
  • C08L39/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
  • C08L39/06—Homopolymers or copolymers of N-vinyl-pyrrolidones

Definitions

• the universal hydrophilic and differential diffuser is known.
• a low-cost matrix that is suitable for the introduction of a wide range of medicinal products with a speed that exceeds the speed of medical products g ⁇ livinil ⁇ v ⁇ g ⁇ s ⁇ i ⁇ a with m ⁇ le ⁇ ulya ⁇ n ⁇ y mass ⁇ 100.000-150.000
• U ⁇ azannaya task ⁇ eshae ⁇ sya ⁇ em, ch ⁇ in s ⁇ s ⁇ ave ⁇ lime ⁇ - 5 n ⁇ y di ⁇ uzi ⁇ nn ⁇ y ma ⁇ itsy AJ ⁇ ansde ⁇ mayan ⁇ g ⁇ vvede ⁇ iya left- ⁇ a ⁇ s ⁇ venny ⁇ vesches ⁇ v, s ⁇ de ⁇ zhaschem binder - ⁇ livinil ⁇ i ⁇ lid ⁇ n, and ⁇ las ⁇ i ⁇ i ⁇ a ⁇ le ⁇ a ⁇ s ⁇ venn ⁇ e vesches ⁇ v ⁇ , s ⁇ glasn ⁇ zayavlyaem ⁇ mu iz ⁇ b ⁇ e ⁇ eniyu in ⁇ aches ⁇ ve svyazuyuscheg ⁇ s ⁇ de ⁇ zhi ⁇ sya ⁇ livinil ⁇ i ⁇ lid ⁇ n with m ⁇ le ⁇ ulya ⁇ n ⁇ y mass ⁇ y ⁇ 500 ⁇ ys. to
• a polyethylene glycol is used with a molecular weight of 300-600, which is a pure, colorless, viscous liquid. We are happy with the situation in the economy, water, and a lot of organic products. 0
• the use of polietilenglikol with a mass of more than 600 reduces the elasticity and adhesion of the matrix.
• the use of polyethylene with a molecular mass below 300 does not allow to receive the matrix from the required range.
• leader causes a decrease in the speed of exit of medicinal material, a stitching of adhesive material, and also deterioration of its weight.
• the present invention is in the pharmaceutical industry.
• the conditions for the increase in the release of the product and the longer the use of the goods are longer - 6 - insert the filler into the system.
• the speed of delivery of the pharmaceutical product may be increased due to the introduction of the product
• ⁇ ⁇ ezul ⁇ a ⁇ e ⁇ i is ⁇ lz ⁇ vanii ma ⁇ itsy with na ⁇ lni ⁇ elem ⁇ zayavlyaem ⁇ mu iz ⁇ b ⁇ e ⁇ eniyu s ⁇ an ⁇ vi ⁇ sya v ⁇ zm ⁇ zhnym is ⁇ lz ⁇ vanie le ⁇ a ⁇ s ⁇ venny ⁇ vesches ⁇ v for ⁇ - ⁇ y ⁇ ⁇ e ⁇ a ⁇ ev ⁇ iches ⁇ y u ⁇ ven ⁇ ntsen ⁇ schy in ⁇ lazme ⁇ vi not m ⁇ zhe ⁇ by ⁇ d ⁇ s ⁇ ignu ⁇ with ⁇ imeneniem izves ⁇ ny ⁇ ma ⁇ its.
• Tungsten fillers with maximum absorption per unit mass possess the best properties. -
• composition proposed in the present invention may contain a combination of medicinal substances 5 after, for example, ⁇ -decyl-2); ⁇ , ⁇ - dimethyl-m-toluamide; dimethyl sulfide; ⁇ - methyl pyrrholide.
• These named components are contained in the claimed composition in quantities, equal to 1-10 parts by weight.
• the composition receives an acceptable diffused matrix for the delivery of 15 medications by means of payment for the services provided.
• a film of, for example, polyethylene, polyethylene, polyvinyl chloride is normally used. It is preferable to use a low-temperature polyethylene film, a simple layer of metallic aluminum with a com- pletion-free housing.
• the ban of the layer claimed by the company is carried out by the usual method of fuel from the factory. On the part of the manufacturer for this, use ethyl alcohol, or any mixture of them.
• the dried layer with a thickness of 50 ⁇ m to I mm is the specified 25 composition and is a materiel.
• This is a flexible, ⁇
• the patient received from the claimed system does not allow the use of a medicinal product (there is a large volume of medical problems). With this, the delivery of the medicine is -9- The vein of matter in an organism is carried out with a constant, independent of time. However, the speed of the trance-dermal delivery of the proprietary panel is claimed to be 47 mkg / cm hour (and, of course, is still small).
• the speed of the transdermal delivery of a nitroglycerin from a flexible diffused matrix is claimed to be 39 ⁇ g / cm “hour.
• the duration of the validity of the matrix is claimed in the invention, the composition reaches seven days.
• the inventive composition of a flexible diffuser matrix is available through the use of a method of liquid processing.
• composition that includes 100 g of polyvinylpyrrolide with a mass of 500 tons. up to 1500 tons , 54, 5 g of polyethylene with a molecular weight of 400, 12 g
• the 35 new pigs sold a dampened pad dipped in water and laid a diffused matrix on it.
• the matrix obtained on the basis indicated above is numbered, it is long-term impaired, because the material received on the basis of the above is inconveniently incurred.
• - 10 - ' fixed on another live bandage.
• the content of hydralazine in live animals was divided by a gas analyzer.
• the area of the matrix is 50 cm 2 (2.2 ⁇ / ⁇ ).
• Table 3 The content of hydrazalazine in small pigs and pansum transformer from a diffusion matrix
• the plant which is manufactured on the basis of a basic, on-board, composition, including 100 g of polivinylllide, is with a mass of 500 thousand. - 1,500 thousand, 52.2 polyethylene with a molecular mass of 400 and 27.2 grams of alcohol, was studied in experiment on six circulators (table 4).
• Tax Data - 13 - were obtained in experiments on kryssakh and skazha. The obtained data of an experimental study of the pharmacokinetics of the matrix with the processor are in full compliance with the therapeutic processes,
• the specific beta-adrenergic activity of diffused mate- rials with impurity is tolerated as an admixture of diabetes.
• the laminate of the diffused matrix with the epidermis of the skin is loaded onto the magnetic stirrer of the zinc disinfectant. After a specified time is removed from the device, the device is in contact with the user when it is in use,
• hydralazine 0.6 g is dissolved in 330 ml of ethanol, containing 33.0 g of polyethylene with a molecular weight of 300, and then added 100 g of dry weight is averaged over 500 ml. The mixture is stirred for a complete recovery of the polymer and the production of the mixture with a viscosity of 400 Poise.
• Example 3 15 Prepares a solution in 400 ml of ethanol 25 hydrazazine, Z3 ' , 3 g polietilenglikol with a molecular weight of 600 and 100 g poli-vinylpyrrolide with a mass of 1,500 mol. It receives a matrix similar to Example I. The resulting matrix provides a transverse reduction of hydralazine at a rate of 20 at 70 mkg / cm ⁇ "hour. ACTIVITY - 4 days. The cost of using a drug - $ 80. Adhesion ⁇ is also 78 g / cm.
• the solution in 400 ml of ethanol is 27.2 g of propanol, 30 55.2 g of polyethylene glycol with a molecular weight of 400 and 100 g of polyvinylpyrrolide with a mass of 1,500 mass. It will receive the analogous method I. The resulting matrix will ensure that the transducer is completely reduced by 47 mg / cm ⁇ - more. DURATION OF ACTIVITY - 6 days, 35 coefficient of use of medicinal material - 80. Adhesion ⁇ ⁇ réelle ⁇ réelle - - 76 n / m ..
• Adhesion ⁇ is also - 73 ⁇ N / m.
• the resulting matrix ensures that the concentrate is not affected.
• Example II 20 Prepare a solution in 400 ml of ethanol 25 g of propanol,
• Example 15 They receive a matrix of Example 15, using 28.6 g of varamil in the quantity of medicinal material and in quantity . 15 of the filler 51 g of the refrigerated material with a ratio of water absorption to the mass equal to 6.98.
• the resulting matrix ensures that the transformer is fully displaced with a speed of 19 mkg / cm 2 "hour (without a filler - 14 mak / cm 2 " hour).
• the validity of the action is 5 days, the coefficient of use of 20 medicinal substances is $ 74.
• Adhesion ⁇ is also 80 n / m.
• Example 19 Example 19
• Zayavlyaem ⁇ e iz ⁇ b ⁇ e ⁇ enie m ⁇ zhe ⁇ by ⁇ is ⁇ lz ⁇ van ⁇ in ⁇ a ⁇ ma- tsev ⁇ iches ⁇ y ⁇ myshlenn ⁇ s ⁇ i and sels ⁇ m ⁇ zyays ⁇ ve in ⁇ aches ⁇ - ve le ⁇ a ⁇ s ⁇ venny ⁇ ⁇ m dli ⁇ eln ⁇ g ⁇ deys ⁇ viya with ⁇ n ⁇ li ⁇ ue- m ⁇ y s ⁇ s ⁇ yu ⁇ dachi le ⁇ a ⁇ s ⁇ venn ⁇ g ⁇ vesches ⁇ va in ⁇ ganizm 35 chel ⁇ ve ⁇ a or zhiv ⁇ n ⁇ g ⁇ .

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical & Material Sciences (AREA)
• Dermatology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Polymers & Plastics (AREA)
• Organic Chemistry (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Materials For Medical Uses (AREA)
• Compositions Of Macromolecular Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=21331698

Family Applications (1)

Country Status (4)

Cited By (10)

Families Citing this family (3)

Citations (5)

Family Cites Families (1)

• 1987
  • 1987-10-23 SU SU874316266A patent/SU1705319A1/ru active
• 1988
  • 1988-04-27 WO PCT/SU1988/000104 patent/WO1989003859A1/ru not_active Ceased
  • 1988-04-27 JP JP63506465A patent/JPH02501982A/ja active Granted
  • 1988-04-27 EP EP19880907444 patent/EP0340307A4/de not_active Withdrawn

Patent Citations (5)

Also Published As

Similar Documents

Legal Events